The pharmaceutical trader cut its quarterly loss by 47% year-on-year, but its revenue base is just ₹0.03 crore, raising questions about its operational scale.
Ortin Global's Q2 FY27 loss narrowed significantly as expenses fell, yet revenue remains at a negligible ₹0.03 crore. The company's future hinges on a leadership overhaul and a potential open offer, not on its current trading business.
For Ortin Global, the story is less about quarterly performance and more about corporate survival. The September quarter saw a smaller loss, but the underlying business is barely generating any sales, leaving investors to watch a leadership transition and a potential change in control.
The numbers show a company shrinking its losses while its top line remains microscopic. Revenue tripled year-on-year to ₹0.03 crore, but that is up from an almost non-existent base. The net loss improved to ₹0.27 crore, a 47% reduction from the year-ago period.
Revenue & profit
Revenue (₹ Cr)
Net Profit (₹ Cr)
Revenue (₹ Cr)
Net Profit (₹ Cr)
| Metric | CurrentQ2 FY27 (Sep 2026) | PreviousQ1 FY27 (Jun 2026) |
|---|---|---|
| Revenue (₹ Cr) | 0.03 | 0.02 |
| Net Profit (₹ Cr) | -0.27 | -0.34 |
The improvement in the bottom line came entirely from cost control, not sales growth. A report from ScanX noted that total expenses fell 41% year-on-year, primarily due to a sharp drop in other expenditure. Employee costs, however, remained a fixed burden, rising slightly. The company's pharmaceutical trading and real estate operations are not driving meaningful income.
With no operational turnaround in sight, the market's focus has shifted. In September, the company overhauled its leadership, appointing a new Managing Director. More significantly, an open offer for a 26% stake by Mr. Parveen Satija at ₹14.65 per share was recommended by independent directors, as reported by FlashFinance. This corporate action, not quarterly sales, is the current driver of investor attention.
Key Points
The quarter confirms Ortin Global is in a holding pattern. Cost cuts can only shrink losses so far when revenue is virtually zero. The company's manufacturing license was cancelled years ago, and its shift to trading has not gained traction. The path forward now depends on the outcome of the open offer and whether new leadership can articulate a viable business plan. Until then, it remains a corporate shell with a listed status, where balance-sheet management outweighs operational performance.
Live Chart
· ORTINGLOBE
(BSE)
ISIN: INE749B01020
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.